An observational study in Metastatic Breast Cancer, Drug Resistance and Hormone Receptor-Positive Breast Cancer, sponsored by Hunan Cancer Hospital. Recruiting at 1 site in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-07-18.
Sponsored by Hunan Cancer Hospital · Observational
This is a real-world observational study aiming to evaluate the effectiveness of post-progression treatment strategies in patients with advanced breast cancer who have developed resistance to prior targeted therapies, including CDK4/6 inhibitors, PIK3CA inhibitors, trastuzumab deruxtecan (T-DXd), or other targeted agents commonly used in clinical practice. As resistance to these therapies becomes increasingly common, optimal sequencing strategies for subsequent treatment remain unclear.
This study will collect clinical information on post-resistance systemic treatments and their outcomes, including progression-free survival, overall survival, and response rate. Baseline patient and tumor characteristics will also be collected to explore potential prognostic and predictive factors and to develop outcome prediction models that may help guide future clinical decision-making.
This is a non-interventional study based on retrospective and prospective data from routine medical care. The results are expected to provide real-world evidence to inform personalized treatment strategies for patients with advanced breast cancer following resistance to targeted therapies.
Breast cancer is a heterogeneous disease, and advances in targeted therapies have significantly improved clinical outcomes, especially in hormone receptor-positive (HR+), HER2-positive, and selected triple-negative breast cancer (TNBC) subtypes. However, disease progression following treatment with targeted agents such as CDK4/6 inhibitors, PIK3CA inhibitors, and antibody-drug conjugates like trastuzumab deruxtecan (T-DXd) remains a major clinical challenge. With a growing number of post-resistance treatment options available, real-world data are urgently needed to inform evidence-based sequencing strategies in routine clinical practice.
This real-world observational study aims to investigate the treatment patterns and clinical outcomes of patients with advanced or metastatic breast cancer who experience disease progression after receiving CDK4/6 inhibitors, PIK3CA inhibitors, T-DXd, or other relevant targeted agents. The study will focus on characterizing the effectiveness of subsequent treatment regimens, including chemotherapy, endocrine therapy, additional targeted therapies, or their combinations.
In addition to evaluating clinical outcomes such as progression-free survival (PFS), overall survival (OS), objective response rate (ORR), and duration of response (DoR), the study will collect detailed baseline patient characteristics, tumor biological features, and prior treatment histories. These data will be used to identify potential prognostic and predictive factors and to develop outcome prediction models that may support personalized treatment planning in the post-resistance setting.
Patients will be identified based on medical record review, with retrospective and/or prospective data collection depending on institutional capabilities. Treatment decisions are made at the discretion of the treating physicians as part of standard clinical care. The study does not involve any experimental intervention, and no additional diagnostic or therapeutic procedures will be imposed on participants.
The ultimate goal of this study is to generate clinically relevant, real-world evidence to guide optimal treatment sequencing after resistance to targeted therapy in advanced breast cancer, and to support future clinical research and decision-making frameworks.
12,544 studies on the registry are indexed under Breast Neoplasms; 2,892 are open to participants now.
This study's planned enrollment of 200 is close to the median of 184 across 2,642 observational studies indexed under Breast Neoplasms.
Browse Breast Neoplasms studies →Hunan Cancer Hospital is the lead sponsor of 54 studies on the registry; 28 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Patients with advanced breast cancer who developed resistance to targeted therapies and subsequently received systemic treatment in routine clinical practice. The study population includes diverse subtypes (HR+/HER2-, HER2+, TNBC) and reflects real-world treatment patterns in post-progression settings.
Exclusion Criteria:
This cohort includes patients with advanced or metastatic breast cancer who experienced disease progression after treatment with CDK4/6 inhibitors, PIK3CA inhibitors, trastuzumab deruxtecan (T-DXd), or other targeted therapies. All patients subsequently received further systemic therapy, including chemotherapy, endocrine therapy, targeted agents, or their combinations, based on physician discretion and routine clinical practice. This observational cohort will be analyzed to assess treatment patterns, clinical outcomes (e.g., progression-free survival and overall survival), and potential prognostic or predictive factors.
Progression-Free Survival (PFS)
Progression-Free Survival (PFS) is defined as the time from the initiation of post-progression systemic treatment (after resistance to CDK4/6 inhibitors, PIK3CA inhibitors, T-DXd, or other targeted therapies) to the date of documented disease progression or death from any cause, whichever occurs first. Disease progression will be determined based on radiological or clinical assessment, as per real-world documentation standards. Patients without progression or death at the time of analysis will be censored at the date of last follow-up.
Time frame: From the start of post-resistance systemic treatment until documented disease progression or death, up to 36 months.
Overall Response Rate (ORR)
ORR is defined as the proportion of patients achieving a complete response (CR) or partial response (PR) to the post-progression systemic treatment, as assessed by the treating physician based on radiological or clinical documentation. Response assessment will follow real-world clinical practice without central review.
Time frame: From start of post-resistance systemic treatment to best documented response, assessed up to 24 months.
Disease Control Rate (DCR)
DCR is defined as the proportion of patients who achieve complete response (CR), partial response (PR), or stable disease (SD) for at least 8 weeks after initiating post-resistance therapy. Evaluations are based on clinical or imaging assessment as documented in routine practice.
Time frame: From treatment initiation to disease progression or last follow-up, assessed up to 24 months.
Overall Survival (OS)
OS is defined as the time from the initiation of post-resistance systemic therapy to death from any cause. Patients still alive at the time of analysis will be censored at their last known follow-up date.
Time frame: From start of post-progression treatment to death or last follow-up, up to 48 months.
Treatment-Related Adverse Events
The incidence and type of treatment-related adverse events (AEs) will be collected as documented in the medical record, based on physician assessment. AEs will be classified according to the Common Terminology Criteria for Adverse Events (CTCAE) version 5.0, where available.
Time frame: From the start of post-resistance treatment until 30 days after treatment discontinuation, assessed up to 24 months.
Plan to share: Undecided
No publications or documents are linked to this record.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Hunan Cancer Hospital